secwatch / observer
8-K filed May 4, 2026, 7:59 PM ET ticker GYRE CIK 0001124105
M&A confidence high sentiment positive materiality 0.85

Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO

GYRE THERAPEUTICS, INC.

item 2.01item 5.03item 1.01item 3.02item 3.03item 5.02item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001140361-26-018716
form_type
8-K
ticker
GYRE
cik
0001124105
company_name
GYRE THERAPEUTICS, INC.
filed_at
2026-05-04T23:59:59+00:00
discovered_at
2026-05-14T18:02:31.979938+00:00
generated_at
2026-05-14T23:49:41.717002+00:00
sec_items
["2.01", "5.03", "1.01", "3.02", "3.03", "5.02", "7.01", "9.01"]
event_type
m_and_a
sentiment
positive
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001140361-26-018716
json_url
https://secwatch.observer/filing/0001140361-26-018716.json
markdown_url
https://secwatch.observer/filing/0001140361-26-018716.md
text_url
https://secwatch.observer/filing/0001140361-26-018716.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ying Luo

Chief Executive Officer, President, Director
GYRE · GYRE THERAPEUTICS, INC.
Effective
2026-05-04
Filed
May 4, 2026, 7:59 PM ET
effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
Departed

Songjiang Ma

Director, President
GYRE · GYRE THERAPEUTICS, INC.
Effective
2026-05-04
Filed
May 4, 2026, 7:59 PM ET
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.
Departed

Ruoyu Chen

Chief Financial Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2026-05-04
Successor
Thomas Eastling
Filed
May 4, 2026, 7:59 PM ET
Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
Departed

Thomas Eastling

Director and Member of Committees
GYRE · GYRE THERAPEUTICS, INC.
Effective
2026-05-04
Filed
May 4, 2026, 7:59 PM ET
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members
Appointed

Thomas Eastling

Chief Financial Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2026-05-04
Filed
May 4, 2026, 7:59 PM ET
the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.

Source-grounded claims

625621074d

Ying Luo was appointed as Chief Executive Officer, President, Director at GYRE THERAPEUTICS, INC..

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

79fee6d5d0

Songjiang Ma resigned as Director, President at GYRE THERAPEUTICS, INC..

Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

8fa097cf45

Ruoyu Chen resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..

Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

e4a28f749d

Thomas Eastling resigned as Director and Member of Committees at GYRE THERAPEUTICS, INC..

Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

f45c7cb789

Thomas Eastling was appointed as Chief Financial Officer at GYRE THERAPEUTICS, INC..

the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

3250af831e43eef4643dd16a2bf9f9c47cf3d8f3

GYRE THERAPEUTICS, INC.: Filed a Certificate of Designation creating a new series of preferred stock in connection with a merger.

The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

6841749b52a7e3f7b6d3ebad252a6e349897ec88

GYRE THERAPEUTICS, INC. completed an acquisition involving Cullgen Inc. for all-stock transaction that valued Cullgen at approximately $300 million (closed 2026-05-04).

Revenue Code of 1986, as amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen

SEC 8-K Item 2.01/5.01 confidence 0.9 SEC evidence

Comparable filings

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: executive_change, ma_transaction same SEC item: 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

Comparable filing

Todd Schell, designated by Warburg, was appointed to serve as a director of OceanFirst

Filing page SEC filing

Enviri II Corp

New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA

Enviri II Corp June 1, 2026, 5:18 PM ET m_and_a Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01

same fact type: governance_change, ma_transaction same SEC item: 1.01, 3.03, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.

Comparable filing

In connection with the Spin-Off, the Board adopted the Code of Conduct, a copy of which is available on New Enviri’s website at www.enviri.com.

Filing page SEC filing

GIG

Hadron Energy closes SPAC merger with GigCapital7; 84% of public shares redeemed

GigCapital7 Corp. May 29, 2026, 7:45 PM ET m_and_a Items 2.01, 3.02, 5.02, 9.01, 3.03, 4.01, 5.01, 5.03, 5.06, 8.01

same fact type: executive_change same SEC item: 2.01, 3.02, 3.03, 5.02, 5.03, 9.01 same event type: m_and_a similar materiality

This filing

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

Comparable filing

and each of the directors having been elected by the GigCapital7 stockholders to the board also upon the Closing on May 22, 2026

Filing page SEC filing

CECO

CECO Environmental completes acquisition of Thermon Group Holdings, issues ~22.5M shares and pays $329.4M cash

CECO ENVIRONMENTAL CORP June 1, 2026, 9:16 AM ET m_and_a Items 2.01, 2.03, 5.02, 5.03, 7.01, 9.01

same fact type: executive_change same SEC item: 2.01, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

Comparable filing

the Board appointed Todd Gleason, CECO’s Chief Executive Officer and an existing member of the Board, to serve as Chairman of the Board, effective as of the effective time of the First Merger.

Filing page SEC filing

FFIC

OceanFirst completes acquisition of Flushing Financial; FFIC holders receive 0.85 OCFC shares

FLUSHING FINANCIAL CORP June 1, 2026, 5:21 PM ET m_and_a Items 2.01, 3.01, 3.03, 5.01, 5.02, 9.01

same fact type: ma_transaction same SEC item: 2.01, 3.03, 5.02, 9.01 same event type: m_and_a similar materiality

This filing

Revenue Code of 1986, as amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

Filing page SEC filing

RPAY

REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan

Repay Holdings Corp June 1, 2026, 4:14 PM ET m_and_a Items 1.01, 2.01, 1.02, 9.01, 2.03, 7.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

Revenue Code of 1986, as amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen

Comparable filing

KUBRA became an indirect wholly owned subsidiary of the Company. Pursuant to the Purchase Agreement, the aggregate cash purchase price for the Acquisition was approximately $372 million, subject to customary post-closing adjustments. The closing cash consideration was funded with a combination of cash on hand and borrowings under the Credit Agreement described

Filing page SEC filing

FDX

FedEx completes spin-off of FedEx Freight; 80.1% distributed to FDX stockholders

FEDEX CORP June 1, 2026, 6:42 AM ET m_and_a Items 1.01, 2.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 1.01, 2.01, 5.02, 9.01 same event type: m_and_a similar materiality

This filing

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

Comparable filing

John A. Smith resigned from his position as Chief Operating Officer, United States and Canada of FedEx, effective as of immediately prior to the Effective Time to become the President and Chief Executive Officer of FedEx Freight.

Filing page SEC filing

AVO

Mission Produce completes acquisition of Calavo Growers for $26.05 per share

Mission Produce, Inc. May 29, 2026, 6:02 AM ET m_and_a Items 2.01, 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 2.01, 5.02, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.

Comparable filing

In connection with the closing of the Mergers, effective as of the Closing Date, Kathleen Holmgren was appointed to the Board of Directors of the Company (the “ Board ”).

Filing page SEC filing

Source: SEC EDGAR
accession 0001140361-26-018716
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.